Douglas Lorne Arnold, MD, FRCP(C)
McGill University
H-index: 123
North America-Canada
Top articles of Douglas Lorne Arnold, MD, FRCP(C)
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Brain volume increase after discontinuing natalizumab therapy: Evidence for reversible pseudoatrophy | Mult Scler Relat Disord [PMID: 37976981; Epub: 2023/11/18] | K Nakamura C Elliott H Lee S Narayanan DL Arnold | 2024 |
Assessing the utility of magnetic resonance imaging-based "SuStaIn" disease subtyping for precision medicine in relapsing-remitting and secondary progressive multiple sclerosis | Multiple Sclerosis and Related Disorders | Xiaotong Jiang Changyu Shen Bastien Caba Douglas L Arnold Colm Elliott | 2023/9/1 |
Single-timepoint low-dimensional characterization and classification of acute versus chronic multiple sclerosis lesions using machine learning | NeuroImage | Bastien Caba Alexandre Cafaro Aurelien Lombard Douglas L Arnold Colm Elliott | 2023/1/1 |
Deviation From Normative Whole Brain and Deep Gray Matter Growth in Children With MOGAD, MS, and Monophasic Seronegative Demyelination | Neurology | Giulia Fadda Alonso Cardenas de la Parra Julia O'Mahony Patrick Waters E Ann Yeh | 2023/7/25 |
A cross-sectional study of MRI features and the gut microbiome in pediatric-onset multiple sclerosis | Ann Clin Transl Neurol [PMID: 38130033; Epub: 2023/12/22] | F Zhu Y Zhao DL Arnold A Bar-Or CN Bernstein | 2023 |
Magnetization transfer saturation reveals subclinical optic nerve injury in pediatric-onset multiple sclerosis | Multiple Sclerosis Journal | Giulia Longoni Edgar Martinez Chavez Kimberly Young Robert A Brown Sonya Bells | 2023/2 |
Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging | Mult Scler [PMID: 37148240; Epub: 2023/05/06] | S Kolind L Gaetano HE Assemlal C Bernasconi U Bonati | 2023 |
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study | Sibyl Wray Barry A Singer Jelena Drulovic Hailu Chen Jennifer Lyons | 2022/5/3 | |
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for … | Multiple Sclerosis and Related Disorders | Lana Zhovtis Ryerson John F Foley Gilles Defer Jeffrey A Cohen Douglas L Arnold | 2023/4/1 |
Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial | Multiple Sclerosis Journal | Jens Kuhle Tanuja Chitnis Brenda Banwell Marc Tardieu Douglas L Arnold | 2023/3 |
Deep learning, data ramping, and uncertainty estimation for detecting artifacts in large, imbalanced databases of MRI images | Medical Image Analysis | Ricardo Pizarro Haz-Edine Assemlal Sethu K Boopathy Jegathambal Thomas Jubault Samson Antel | 2023/12/1 |
Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis | Multiple Sclerosis Journal | Colm Elliott David A Rudko Douglas L Arnold Dumitru Fetco Ahmed M Elkady | 2023/5 |
Networks of microstructural damage predict disability in multiple sclerosis | Journal of Neurology, Neurosurgery & Psychiatry | Elisa Colato Ferran Prados Jonathan Stutters Alessia Bianchi Sridar Narayanan | 2023/12/1 |
Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective | Massimo Filippi Paolo Preziosa Douglas L Arnold Frederik Barkhof Daniel M Harrison | 2023/3 | |
Chronic lesion activity and disability progression in secondary progressive multiple sclerosis | BMJ neurology open | Vanessa Beynon Ilena C George Colm Elliott Douglas L Arnold Jun Ke | 2022 |
Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria | Multiple Sclerosis Journal | Giulia Fadda Patrick Waters Mark Woodhall Robert A Brown Julia O’Mahony | 2022/10 |
Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and … | Frontiers in immunology | Tjalf Ziemssen Douglas L Arnold Enrique Alvarez Anne H Cross Roman Willi | 2022/3/31 |
How patients with multiple sclerosis acquire disability. | Brain | Fred D Lublin Dieter A Häring Habib Ganjgahi Alex Ocampo Farhad Hatami | 2022/9/1 |
The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome | Multiple Sclerosis and Related Disorders | Ali I Mirza Feng Zhu Natalie Knox Jessica D Forbes Christine Bonner | 2022/7/1 |
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial | Multiple Sclerosis Journal | Bruce AC Cree Krzysztof W Selmaj Lawrence Steinman Giancarlo Comi Amit Bar-Or | 2022/10 |
Co-Authors
